Words of Wisdom: re: international variation in prostate cancer incidence and mortality rates.

H. Kuruma,S. Egawa

DOI: https://doi.org/10.1016/j.eururo.2012.12.012

IF: 24.267

European Urology

Abstract:

What problem does this paper attempt to address?

Anti-inflammatory potency of oral disulfiram compared with dexamethasone on endotoxin-induced uveitis in rats.

K. Kanai,N. Itoh,Yoshimasa Ito,N. Nagai,Y. Hori,S. Chikazawa,F. Hoshi,S. Higuchi

DOI: https://doi.org/10.1292/JVMS.10-0239

2011-04-01

Journal of Veterinary Medical Science

Abstract:To investigate potency of oral disulfiram (DSF) compared with that of dexamethasone (Dexa), on endotoxin-induced uveitis (EIU) in rats. The oral administration with 750 mg/kg DSF suppressed the number of inflammatory cells, protein concentration, and levels of tumor necrosis factor (TNF)-α, Nitric oxide (NO) and prostaglandin (PG) E2 in the aqueous humor and improved the histiologic status of the ocular tissue at 24 hr after lipopolysaccharide (LPS) injection. The anti-inflammatory potency of DSF oral administration was as strong as that observed with 0.5 mg/kg Dexa in the present study. The results suggest that DSF might pave the way for a novel therapeutic agent for the management of uveitis.
Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment

Luca Marsili,Samuel Marcucci,Joseph LaPorta,Martina Chirra,Alberto J. Espay,Carlo Colosimo

DOI: https://doi.org/10.3390/biomedicines11051406

IF: 4.757

2023-05-10

Biomedicines

Abstract:Paraneoplastic neurological syndromes (PNS) include any symptomatic and non-metastatic neurological manifestations associated with a neoplasm. PNS associated with antibodies against intracellular antigens, known as "high-risk" antibodies, show frequent association with underlying cancer. PNS associated with antibodies against neural surface antigens, known as "intermediate- or low-risk" antibodies, are less frequently associated with cancer. In this narrative review, we will focus on PNS of the central nervous system (CNS). Clinicians should have a high index of suspicion with acute/subacute encephalopathies to achieve a prompt diagnosis and treatment. PNS of the CNS exhibit a range of overlapping "high-risk" clinical syndromes, including but not limited to latent and overt rapidly progressive cerebellar syndrome, opsoclonus-myoclonus-ataxia syndrome, paraneoplastic (and limbic) encephalitis/encephalomyelitis, and stiff-person spectrum disorders. Some of these phenotypes may also arise from recent anti-cancer treatments, namely immune-checkpoint inhibitors and CAR T-cell therapies, as a consequence of boosting of the immune system against cancer cells. Here, we highlight the clinical features of PNS of the CNS, their associated tumors and antibodies, and the diagnostic and therapeutic strategies. The potential and the advance of this review consists on a broad description on how the field of PNS of the CNS is constantly expanding with newly discovered antibodies and syndromes. Standardized diagnostic criteria and disease biomarkers are fundamental to quickly recognize PNS to allow prompt treatment initiation, thus improving the long-term outcome of these conditions.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Updates in the Management of Paraneoplastic Syndrome

Neha Verma,Muhammad H. Jaffer,Avinash S. Kolli,Sepideh Mokhtari

DOI: https://doi.org/10.1055/s-0043-1777353

2024-01-08

Seminars in Neurology

Abstract:Paraneoplastic neurological syndromes (PNS) are defined as remote neurologic immune-mediated effects triggered by underlying systemic tumors. While recognizing specific syndromes can aid early cancer detection, overutilization of paraneoplastic assays in the absence of a classic syndrome can precipitate overdiagnosis and overtreatment. PNS involve autoantibodies targeting intracellular or extracellular antigens, with variable immunotherapy responses based on antigen type. Diagnosing PNS is challenging, requiring exclusion of other differential diagnoses. New diagnostic criteria classify PNS into high-risk and intermediate-risk phenotypes based on clinical phenotype, neuronal antibodies, and cancer presence. Patients with cell surface antibodies respond better to immunotherapies compared to those with intracellular antigen targets. Understanding PNS syndromes, serological markers, and oncological features guides management, which facilitates initiation of immunosuppression for PNS alongside treatment of the underlying neoplasm, thereby improving neurologic and oncologic outcomes. Initial treatments often include intravenous methylprednisolone, plasma exchange, or intravenous immunoglobulins. Second-line immunosuppressants like rituximab or cyclophosphamide may be necessary if initial treatments fail. Specific therapies vary based on antibody target. Here, we summarize the current approach to the investigation, diagnosis, and treatment of patients with suspected PNS. * Co–first authors Article published online: 06 January 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

clinical neurology
Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors

Sophie L. Duong,Harald Prüss

DOI: https://doi.org/10.1007/s13311-022-01184-0

IF: 6.088

2022-01-18

Neurotherapeutics

Abstract:Abstract The introduction of immune checkpoint inhibitors (ICIs) in oncologic therapies has led to a paradigm shift in cancer treatment. ICIs have increased the overall survival in patients with malignant melanoma, small-cell lung cancer, and many other tumor entities. Despite their clinical benefits, these novel cancer immunotherapies can induce neurological immune-related adverse events (irAEs). Such immune-mediated complications can manifest within the spectrum of paraneoplastic neurological syndromes (PNSs). PNSs are rare immune-mediated complications of systemic cancers that can involve every aspect of the nervous system. The emergence of PNSs with ICI treatment opens further pathways to study the complex immunopathological interplay of cancer immunity, cross-reactive neurological autoimmune phenomena, and effects of ICIs on the immune system. ICI-induced PNSs comprise a diverse antibody repertoire and phenotypic spectrum with severe and life-threatening disease progression in some cases. Timely diagnosis and urgent interventions are pivotal for a favorable neurologic and oncologic outcome. This review focuses on the pathogenesis of cancer immunotherapy and the disruption of immune tolerance in PNSs and provides an overview of the most pertinent clinical manifestations and principles of diagnostic and therapeutic managements in light of the expected increase in PNSs due to the widespread use of ICIs in clinical practice. This review further discusses potential and evolving concepts of therapeutic monoclonal antibodies for the treatment of PNSs.

pharmacology & pharmacy,neurosciences,clinical neurology
Paraneoplastic Neuropathies: What's New Since the 2004 Recommended Diagnostic Criteria

Marco Zoccarato,Wolfgang Grisold,Anna Grisold,Valentina Poretto,Federica Boso,Bruno Giometto

DOI: https://doi.org/10.3389/fneur.2021.706169

2021-10-01

Abstract:The diagnostic criteria published by the PNS (Paraneoplastic Neurological Syndromes) Euronetwork in 2004 provided a useful classification of PNS, including paraneoplastic neuropathies. Subacute sensory neuronopathy (SSN) was the most frequently observed peripheral PNS, whereas other forms of neuropathy, as sensory polyneuropathy, sensorimotor polyneuropathy, demyelinating neuropathies, autonomic neuropathies, and focal nerve or plexus lesions, were less frequent. At the time of publication, the main focus was on onconeural antibodies, but knowledge regarding the mechanisms has since expanded. The antibodies associated with PNS are commonly classified as onconeural (intracellular) and neuronal surface antibodies (NSAbs). Since 2004, the number of antibodies and the associated tumors has increased. Knowledge has grown on the mechanisms underlying the neuropathies observed in lymphoma, paraproteinemia, and multiple myeloma. Moreover, other unrevealed mechanisms underpin sensorimotor neuropathies and late-stage neuropathies, where patients in advanced stages of cancer-often associated with weight loss-experience some mild sensorimotor neuropathy, without concomitant use of neurotoxic drugs. The spectrum of paraneoplastic neuropathies has increased to encompass motor neuropathies, small fiber neuropathies, and autonomic and nerve hyperexcitability syndromes. In addition, also focal neuropathies, as cranial nerves, plexopathies, and mononeuropathies, are considered in some cases to be of paraneoplastic origin. A key differential diagnosis for paraneoplastic neuropathy, during the course of cancer disease (the rare occurrence of a PNS), is chemotherapy-induced peripheral neuropathy (CIPN). Today, novel complications that also involve the peripheral nervous system are emerging from novel anti-cancer therapies, as targeted and immune checkpoint inhibitor (ICH) treatment. Therapeutic options are categorized into causal and symptomatic. Causal treatments anecdotally mention tumor removal. Immunomodulation is sometimes performed for immune-mediated conditions but is still far from constituting evidence. Symptomatic treatment must always be considered, consisting of both drug therapy (e.g., pain) and attempts to treat disability and neuropathic pain.
Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors

Andreu Vilaseca,Antonio Farina,Macarena Villagrán-García,Antoine Pegat,Marie Benaiteau,Nicolás Lundahl Ciano-Petersen,Le-Duy Do,Véronique Rogemond,David Gonçalves,Dimitri Psimaras,Cristina Birzu,Jérôme Honnorat,Bastien Joubert

DOI: https://doi.org/10.1007/s00415-024-12252-0

2024-03-13

Journal of Neurology

Abstract:Background The clinical spectrum of melanoma-associated neurological autoimmunity, whether melanoma-associated paraneoplastic neurological syndromes (PNS) or induced by immune checkpoint inhibitors (ICI), is not well characterized. We aim to describe the clinical spectrum of melanoma-associated neurological autoimmunity. Methods A systematic review of the literature combined with patients from French databases of paraneoplastic neurological syndromes was conducted. All melanoma patients with a possible immune-mediated neurologic syndrome were included and classified according to whether they had previously been exposed to ICI (ICI-neurotoxicity) or not (ICI-naïve) at first neurological symptoms. Results Seventy ICI-naïve (literature: n = 61) and 241 ICI-neurotoxicity patients (literature: n = 180) were identified. Neuromuscular manifestations predominated in both groups, but peripheral neuropathies were more frequent in ICI-neurotoxicity patients (39.4% vs 21.4%, p = 0.005) whereas myositis was more frequent in ICI-naïve patients (42.9% vs 18.7%, p < 0.001). ICI-naïve patients had also more frequent central nervous system (CNS) involvement (35.7% vs 23.7%, p = 0.045), classical paraneoplastic syndrome (25.7% vs 5.8%, p < 0.001), and more frequently positive for anti-neuron antibodies (24/32, 75.0% vs 38/90, 42.2%, p = 0.001). Although more ICI-neurotoxicity patients died during the acute phase (22/202, 10.9% vs 1/51, 2.0%, p = 0.047), mostly myositis patients (14/22, 63.6%), mortality during follow-up was higher in ICI-naïve patients (58.5% vs 29.8%, p < 0.001). There was no significant difference in the frequency of life independence (mRS ≤ 2) in the surviving patients in both groups (95.5% vs 91.0%, p = 0.437). Conclusions Melanoma-associated PNS appear remarkably rare. The clinical similarities observed in neurological autoimmunity between ICI-treated and ICI-naïve patients, characterized predominantly by demyelinating polyradiculoneuropathy and myositis, suggest a potential prior immunization against melanoma antigens contributing to ICI-related neurotoxicity.

clinical neurology
An Eight-Year Single-Center Experience

Konstantinos Melanis,Maria-Ioanna Stefanou,Dimitrios K. Kitsos,Athanasia Athanasaki,Aikaterini Theodorou,Eleftheria Koropouli,Anna Keramida,Evangelia Makrina Dimitriadou,Dimitrios Tzanetakos,Elizabeth Andreadou,Ioanna Koutroulou,Sotirios Giannopoulos,George P. Paraskevas,Georgios Tsivgoulis,John S. Tzartos

DOI: https://doi.org/10.3390/jcm13030824

IF: 3.9

2024-02-01

Journal of Clinical Medicine

Abstract:Background: Paraneoplastic Neurological Syndromes (PNS) comprise a diverse group of disorders propagated by immune-mediated effects of malignant tumors on neural tissue. Methods: A single-center longitudinal study was performed including consecutive adult patients treated at a tertiary academic hospital between 2015 and 2023 and diagnosed with PNS. PNS were ascertained using the 2004 and the revised 2021 PNS-Care diagnostic criteria. Results: Thirteen patients who fulfilled the 2004 definite PNS criteria were included. PNS comprise diverse neurological syndromes, with neuromuscular junction disorders (54%) and limbic encephalitis (31%) being predominant. PNS-related antibodies were detected in 85% of cases, including anti-AChR (n = 4), anti-P/Q-VGCC (n = 3), anti-Hu (n = 3), anti-Yo (n = 1), anti-Ma (n = 1), anti-titin (n = 1), anti-IgLON5 (n = 1), and anti-GAD65 (n = 1). Thymoma (31%), small-cell lung cancer (23%), and papillary thyroid carcinoma (18%) were the most frequent tumors. Imaging abnormalities were evident in 33% of cases. Early immunotherapy within 4-weeks from symptom onset was associated with favorable outcomes. At a mean follow-up of 2 ± 1 years, two patients with anti-Hu and anti-Yo antibodies died (18%). Four and three patients fulfilled the 2021 PNS-Care diagnostic criteria for definite and probable PNS, respectively. Conclusions: This study highlights the clinical heterogeneity of PNS, emphasizing the need for early suspicion and prompt treatment initiation for optimal outcomes.

medicine, general & internal
Detection of paraneoplastic antibodies and their significance in paraneoplastic neurologic syndromes: a narrative review

Lin Li,Yanjun Guo,Jiawei Wang

DOI: https://doi.org/10.21037/atm-21-2434

IF: 3.616

2022-12-22

Annals of Translational Medicine

Abstract:Background and Objective: Paraneoplastic neurological syndromes (PNS) are a group of rare syndromes associated with immunopathological process and tumors. Paraneoplastic autoantibodies are important for the diagnosis of PNS and for searching for underlying tumors. With the development of detection methods and discovery of new autoantibodies, the 2004 guidelines on PNS have recently been updated by a worldwide PNS-Care expert group. For clinicians, proper testing methods and testing results explanation are important for the diagnosis and treatment of PNS. This review aims to review the detection of paraneoplastic autoantibodies and the significance of testing results.Methods: We summarize the studies on detection methods, association of autoantibodies and PNS or tumors, particularly the guidelines of PNS.Key Content and Findings: Antibodies are divided into 3 groups in the context of PNS according to the frequency of cancer association regardless of their eventual pathogenic effect. Instead of well-characterized antibodies and partially-characterized antibodies, high-risk antibodies, intermediate risk antibodies and lower risk antibodies were applied. According to the location of recognized antigens, these autoantibodies are divided as anti-intracellular antigen antibodies and neuronal surface antibodies (NSAbs). Tissue-based assays is recommended as screening method for paraneoplastic antibodies. Moreover, this method is helpful to discover new autoantibodies. A combination of a screening method [tissue-based assays (TBA)] and a confirmatory test [immunoblot and cell-based assay (CBA)] can improve sensitivity and specificity of the tests. Many PNSs are associated with specific antineuronal antibodies, but there is considerable diversity. Some autoantibodies are markers of specific neurological syndromes. Paraneoplastic antibodies are often specific for the PNS-associated tumor rather than for a particular neurological syndrome.Conclusions: Diagnosis of PNS depends on integrated analysis of clinical manifestations and auxiliary examinations. During diagnosis, selection of candidate antibodies for testing is challenging due to the varying clinical phenotypes and tumors associated with a given antibody. Broad antibody panels are more likely to capture causative antibodies and should be considered. According to different subtypes of autoantibodies, specific tumors or PNS should be considered. However, antibody titers, including cerebrospinal fluid (CSF) titers, should not be the primary driver of treatment decisions.

oncology,medicine, research & experimental
Paraneoplastic antibodies targeting intracellular antigens

Jenny J Linnoila

DOI: https://doi.org/10.1016/B978-0-12-823912-4.00021-9

Abstract:Although they are relatively rare, the diagnosis of paraneoplastic neurologic syndromes (PNS) can be aided by the identification of neural autoantibodies in patients' serum and cerebrospinal fluid (CSF). They often clinically manifest as characteristic syndromes, including limbic encephalitis, opsoclonus-myoclonus syndrome, paraneoplastic cerebellar degeneration, and paraneoplastic encephalomyelitis. The antibodies are directed either toward intracellular targets, or epitopes on the cell surface. As compared to cell surface antibodies, intracellular paraneoplastic autoantibodies are more classically associated with cancer, most often lung, breast, thymoma, gynecologic, testicular, and/or neuroendocrine cancers. The malignancies themselves tend to be small and regionally contained, attesting to the strength of the immune system in cancer immunosurveillance. Typically, the intracellular antibodies are not directly pathogenic and tend to be associated with PNS that are poorly responsive to treatment. With some notable exceptions, including patients with PNS associated with testicular cancer, patients with intracellular antibodies are typically older individuals, in their 7th decade of life and beyond. Many of them are current or former smokers. Treatment strategies include tumor removal as well as immunotherapy to treat the concomitant PNS. Newer technologies and the ever-broadening use of cancer immunotherapies are contributing to the continued identification of novel intracellularly targeted autoantibodies.
Paraneoplastic Diseases of the Central Nervous System

Jonathan Galli,John Greenlee

DOI: https://doi.org/10.12688/f1000research.21309.1

2020-03-06

F1000Research

Abstract:Paraneoplastic neurological syndromes are nonmetastatic complications of malignancy secondary to immune-mediated neuronal dysfunction or death. Pathogenesis may occur from cell surface binding of antineuronal antibodies leading to dysfunction of the target protein, or from antibodies binding against intracellular antigens which ultimately leads to cell death. There are several classical neurological paraneoplastic phenotypes including subacute cerebellar degeneration, limbic encephalitis, encephalomyelitis, and dorsal sensory neuropathy. The patient’s clinical presentations may be suggestive to the treating clinician as to the specific underlying paraneoplastic antibody. Specific antibodies often correlate with the specific underlying tumor type, and malignancy screening is essential in all patients with paraneoplastic neurological disease. Prompt initiation of immunotherapy is essential in the treatment of patients with paraneoplastic neurological disease, often more effective in cell surface antibodies in comparison to intracellular antibodies, as is removal of the underlying tumor.
A Study on Imbibition and Syneresis in Four Commercially Available Irreversible Hydrocolloid (Alginate) Impression Materials

Shushant K. Garg,S. Mittal,S. Bansal,Gagandeep Kansal

DOI: https://doi.org/10.5005/JP-JOURNALS-10019-1037

2012-01-04

Abstract:Purpose: To evaluate imbibition and syneresis in fourcommercially available irreversible hydrocolloid (alginate)impression materials at different time intervals (10, 20 and 30minutes).Materials and methods: Eighty samples of four commerciallyavailable irreversible hydrocolloid (alginate) impression materialsAlgitex (DPI, Mumbai), Plastalgin (Septodont, Cedex, France),Zelgan 2002 (Dentsply), Finndent (Pyrex Polykem) were made.Twenty samples each of four irreversible hydrocolloid (alginate)impression materials were grouped into four groups (I, II, IIIand IV). Measured quantity of alginate powder and liquid wasused to make samples. The samples were evaluated forimbibition and syneresis at different time intervals (i.e.10, 20,and 30 minutes) by weighing on electronic analytic balance.The data were analyzed using the one-way ANOVA, post hoctest and t-test.Results: The statistical data revealed that imbibition within fourgroups of irreversible hydrocolloid (alginate) impressionmaterials were not significant. Regarding syneresis there wasinsignificant difference between the four groups but within thegroup itself they showed significant difference between themdepending upon the time interval. It was observed that Group Ishowed significant difference in syneresis at time interval of 10to 20 minutes. Group II showed significant difference in syneresisat time interval of 10 to 30 minutes.Conclusion: This study demonstrated that four groups of irreversible hydrocolloid (alginate) impression materials showed different rates of imbibition and syneresis at time interval of 10,20 and 30 minutes depending upon molecular weight, calcium concentration and environmental conditions.
Immune-Mediated Neuropathies: Pathophysiology and Management

Abhishek Shastri,Ahmad Al Aiyan,Uday Kishore,Maria Elena Farrugia

DOI: https://doi.org/10.3390/ijms24087288

IF: 5.6

2023-04-14

International Journal of Molecular Sciences

Abstract:Dysfunction of the immune system can result in damage of the peripheral nervous system. The immunological mechanisms, which include macrophage infiltration, inflammation and proliferation of Schwann cells, result in variable degrees of demyelination and axonal degeneration. Aetiology is diverse and, in some cases, may be precipitated by infection. Various animal models have contributed and helped to elucidate the pathophysiological mechanisms in acute and chronic inflammatory polyradiculoneuropathies (Guillain–Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy, respectively). The presence of specific anti-glycoconjugate antibodies indicates an underlying process of molecular mimicry and sometimes assists in the classification of these disorders, which often merely supports the clinical diagnosis. Now, the electrophysiological presence of conduction blocks is another important factor in characterizing another subgroup of treatable motor neuropathies (multifocal motor neuropathy with conduction block), which is distinct from Lewis–Sumner syndrome (multifocal acquired demyelinating sensory and motor neuropathy) in its response to treatment modalities as well as electrophysiological features. Furthermore, paraneoplastic neuropathies are also immune-mediated and are the result of an immune reaction to tumour cells that express onconeural antigens and mimic molecules expressed on the surface of neurons. The detection of specific paraneoplastic antibodies often assists the clinician in the investigation of an underlying, sometimes specific, malignancy. This review aims to discuss the immunological and pathophysiological mechanisms that are thought to be crucial in the aetiology of dysimmune neuropathies as well as their individual electrophysiological characteristics, their laboratory features and existing treatment options. Here, we aim to present a balance of discussion from these diverse angles that may be helpful in categorizing disease and establishing prognosis.

biochemistry & molecular biology,chemistry, multidisciplinary
Neurological autoimmunity in patients with non‐pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles

Georgios Mangioris,Thorvardur R. Halfdanarson,Vanda A. Lennon,Bryce K. Chang,Divyanshu Dubey,P. James B. Dyck,Eoin P. Flanagan,Andrew McKeon,John R. Mills,Sean J. Pittock,Anastasia Zekeridou

DOI: https://doi.org/10.1111/ene.16273

2024-03-13

European Journal of Neurology

Abstract:Background and purpose Paraneoplastic neurological autoimmunity is well described with small‐cell lung cancer, but information is limited for other neuroendocrine neoplasms (NENs). Methods Adult patients with histopathologically confirmed non‐pulmonary NENs, neurological autoimmunity within 5 years of NEN diagnosis, and neural antibody testing performed at the Mayo Clinic Neuroimmunology Laboratory (January 2008 to March 2023) were retrospectively identified. Control sera were available from patients with NENs without neurological autoimmunity (116). Results Thirty‐four patients were identified (median age 68 years, range 31–87). The most common primary tumor sites were pancreas (nine), skin (Merkel cell, eight), small bowel/duodenum (seven), and unknown (seven). Five patients received immune checkpoint inhibitor (ICI) therapy before symptom onset; symptoms preceded cancer diagnosis in 62.1% of non‐ICI‐treated patients. The most frequent neurological phenotypes (non‐ICI‐treated) were movement disorders (12; cerebellar ataxia in 10), dysautonomia (six), peripheral neuropathy (eight), encephalitis (four), and neuromuscular junction disorders (four). Neural antibodies were detected in 55.9% of patients studied (most common specificities: P/Q‐type voltage‐gated calcium channel [seven], muscle‐type acetylcholine receptor [three], anti‐neuronal nuclear antibody type 1 [three], and neuronal intermediate filaments [two]), but in only 6.9% of controls. Amongst patients receiving cancer or immunosuppressive therapy, 51.6% had partial or complete recovery. Outcomes were unfavorable in 48.3% (non‐ICI‐treated) and neural autoantibody positivity was associated with poor neurological outcome. Discussion Neurological autoimmunity associated with non‐pulmonary NENs is often multifocal and can be treatment responsive, underscoring the importance of rapid recognition and early treatment.

neurosciences,clinical neurology
Paraneoplastic neurologic syndrome and autoantibody accompaniments of germ cell tumors

M Bakri Hammami,Mohamed Rezk,Divyanshu Dubey

DOI: https://doi.org/10.1016/B978-0-12-823912-4.00001-3

Abstract:Paraneoplastic neurologic syndromes (PNSs) are a group of diseases affecting the central and/or peripheral nervous system caused by immune-mediated processes directed toward antigens with shared expression in tumor and neural tissue. Germ cell tumors (GCTs) are associated with PNSs with varied clinical phenotypes. Early diagnosis of PNS is vital to potentially uncover and treat underlying tumors, improving the chances of recovery, and preventing permanent neurologic complications. In this chapter, we outline the pathophysiology and epidemiology of PNS. We briefly provide a summary of GCTs in males and females. We review the neural-specific autoantibodies and PNSs associated with GCTs and their clinical and radiologic accompaniments. We also provide an overview of the treatment and prognosis of these disorders.
Autoimmune diseases of the peripheral nervous system

Bernd C Kieseier,Helmar C Lehmann,Gerd Meyer Zu Hörste

DOI: https://doi.org/10.1016/j.autrev.2011.05.011

Abstract:Autoimmune-mediated diseases targeting the peripheral nerve represent a group of disorders often associated with high clinical disability. At present, therapeutic options are limited. The application of innovative and cutting-edge technologies to the study of immune-mediated disorders of the peripheral nervous system (PNS) have generated a better understanding of underlying principles of the organization of the immune network present in the peripheral nerve and its dialogue with the systemic immune system. These insights may foster the development of specific and highly effective therapies for autoimmune diseases of the peripheral nerve. Of great interest in this context is the application of monoclonal antibodies, such as rituximab or alemtuzumab, which in small observational studies provided promising clinical results. But also other immunomodulatory or immunosuppressive drugs used in other indications currently find their way to PNS autoimmunity. Clearly, prospective controlled clinical trials are warranted before making firm conclusions on the feasibility of these innovative therapeutic approaches for treating immune-mediated disease of the peripheral nerve.
Paraneoplastic autonomic neuropathies and GI dysmotility

Elisabeth P Golden,Steven Vernino

DOI: https://doi.org/10.1016/B978-0-12-823912-4.00005-0

Abstract:A number of the well-recognized autoimmune and paraneoplastic neurologic syndromes commonly involve the autonomic nervous system. In some cases, the autonomic nerves or ganglia are primary targets of neurologic autoimmunity, as in immune-mediated autonomic ganglionopathies. In other disorders such as encephalitis, autonomic centers in the brain may be affected. The presence of autonomic dysfunction (especially gastrointestinal dysmotility) is sometimes overlooked even though this may contribute significantly to the symptom burden in these paraneoplastic disorders. Additionally, recognition of autonomic features as part of the clinical syndrome can help point the diagnostic evaluation toward autoimmune and paraneoplastic etiologies. As with other paraneoplastic disorders, the clinical syndrome and the presence and type of neurologic autoantibodies help to secure the diagnosis and direct the most appropriate investigation for malignancy. Optimal management for these conditions typically includes aggressive treatment of the neoplasm, immunomodulatory therapy, and symptomatic treatments for orthostatic hypotension and gastrointestinal dysmotility.
Paraneoplastic neurological syndromes - patients' cohort profile in the Czech Republic

P Stourac,Z Kadanka,V Palyza

DOI: https://doi.org/10.1034/j.1600-0404.2001.104002072.x

Abstract:Reported paraneoplastic neurological syndromes (PNS) are rare disabling neurological diseases with supposed autoimmune pathogenesis. The aims of this study were to evaluate frequency, clinical course and therapeutic response in the cohort of PNS positive patients (n=10) in the Czech Republic for the first time. Second, we determined the presence and distribution of oligoclonal IgG bands (OB IgG) in PNS and compared the clinical and laboratory features of OB IgG positive and negative patients. A total of 2355 suspicious serum and/or CSF samples were screened by immunofluorescence and immunohistochemistry with definite confirmation by Western blot. OB IgG were detected by isoelectric focusing and immunoenzymatic staining and clinical status was scored according to modified Rankin scale (RS). Four patients had anti-Yo antibody, ovarian cancer and the score in range (2-5) on RS. Five patients had anti-Hu antibody, small cell lung cancer (SCLC), prostate cancer and the score between 1-4 grade on RS. One patient with SCLC and anti-Ri antibody had grade 2. Five of 10 patients with PNS had positive OB IgG and average value 4.2 on RS comparing with negative OB IgG patients with average value 2.6. Finally, we add well-defined cohort of PNS patients to emerging European profile of PNS and conclude that the presence of OB IgG in PNS seems to reflect enhanced immune response with more severe neurological damage and clinical course.
[Mycosis fungoides with ocular manifestations; a case with dysoric retinal disease].

A. Franceschetti

1950-12-01

Abstract:
Hormonal modulation of herpes simplex virus replication in a mouse neuroblastoma cell line

G. P. Sawiris,R. Sydiskis,N. Bashirelahi

DOI: https://doi.org/10.1002/jcla.1860080304

Abstract:In this study, the effect of the synthetic glucocorticoid hormone dexamethasone (DXM) on HSV replication was studied in a DXM receptor‐positive mouse neuroblastoma (NB) cell line. In cells treated with 10−7M DXM and then infected with HSV, there was a statistically significant 9–18‐fold increase in the amount of virus produced in these cells compared to untreated controls. Adsorption kinetic studies with HSV were performed in DXM‐treated NB cells and untreated controls. It was found that there was a significant increase in the adsorption rate of HSV in the DXM‐treated cells as compared with the controls. During the course of these studies, a strain of NB cells was noted to have lost its ability to stimulate HSV replication following DXM treatment. Receptor binding assays were performed on cytosols prepared from NB cells that responded with an increase in HSV titers to DXM treatment and the new strain of NB cells that was DXM refractile. These latter cells were found to have lost their DXM receptors. These results indicate that the modulation of HSV replication of DXM treated cells was regulated by the presence of DXM receptors in these cells. Once lost, the cells do not respond to DXM treatment with increased HSV replication. These observations may lead to a clinical assay to determine patients with high glucocorticoid levels who may be at risk of recurrent herpes infections. © 1994 Wiley‐Liss, Inc.
Neoplasia and the erythron.

D. Doll,R. Weiss

DOI: https://doi.org/10.1200/JCO.1985.3.3.429

IF: 45.3

1985-03-01

Journal of Clinical Oncology

Abstract:Neoplasms may affect the erythroid system in a variety of ways. By far the most common abnormality associated with neoplastic disorders is anemia. It is important to recognize that there are multiple causes of anemia associated with neoplasms, because therapy of the anemia varies according to the causative mechanism. Less commonly, the paraneoplastic syndrome of erythrocytosis may occur in some patients with neoplasia. More subtle abnormalities of the erythrocytes associated with malignant disease include modification of the RBC membrane, changes in erythrocyte enzymes, and abnormalities in hemoglobin production. Clinical awareness of the multiple effects of neoplasms on the erythron will lead to better patient management and may also improve our understanding of erythropoiesis.

Words of Wisdom: re: international variation in prostate cancer incidence and mortality rates.

Anti-inflammatory potency of oral disulfiram compared with dexamethasone on endotoxin-induced uveitis in rats.

Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment

Updates in the Management of Paraneoplastic Syndrome

Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors

Paraneoplastic Neuropathies: What's New Since the 2004 Recommended Diagnostic Criteria

Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors

An Eight-Year Single-Center Experience

Detection of paraneoplastic antibodies and their significance in paraneoplastic neurologic syndromes: a narrative review

Paraneoplastic antibodies targeting intracellular antigens

Paraneoplastic Diseases of the Central Nervous System

A Study on Imbibition and Syneresis in Four Commercially Available Irreversible Hydrocolloid (Alginate) Impression Materials

Immune-Mediated Neuropathies: Pathophysiology and Management

Neurological autoimmunity in patients with non‐pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles

Paraneoplastic neurologic syndrome and autoantibody accompaniments of germ cell tumors

Autoimmune diseases of the peripheral nervous system

Paraneoplastic autonomic neuropathies and GI dysmotility

Paraneoplastic neurological syndromes - patients' cohort profile in the Czech Republic

[Mycosis fungoides with ocular manifestations; a case with dysoric retinal disease].

Hormonal modulation of herpes simplex virus replication in a mouse neuroblastoma cell line

Neoplasia and the erythron.